{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:12:09Z","timestamp":1772165529641,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T00:00:00Z","timestamp":1640390400000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Immunol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>ABP501 is a biosimilar to Reference Adalimumab (HUMIRA\u00ae) produced by AMGEN. Adalimumab (ADA) has a marketing authorization for Crohn's disease, ulcerative colitis and other inflammatory or autoimmune diseases. The aim of this study was to evaluate the LISA-TRACKER assays developed by Theradiag (France), for the monitoring of ABP501 and anti-ABP501 antibodies in human serum.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>68 ABP501 clinical samples were measured with the LISA TRACKER Duo Adalimumab assay. LISA TRACKER has been validated as suitable for quantification of ABP501 in human serum samples. Accuracy of the LISA-TRACKER was measured using 3 human serum matrices spiked with known levels of biosimilar, 3 levels spanning the dynamic range. Percentages of recovery were ranged from 90 to 120% for biosimilar batch1, and between 93 and 105% for biosimilar batch2. The acceptance criteria (CV\u2009&lt;\u200920%) were met for intra-run (from 3.8 to 16.5%) and inter-run imprecision (from 4.4 to 13.9%) including the two batches. All results were comprised within\u2009\u00b1\u200920% from results, obtained with the kit and sample unexposed in order to evaluate stability of the sample, stability of the kit and consistency of the results. In any case, but two, all percentages of inhibition were &gt;\u200950% for specificity. Specificity was tested with Biosimilar spiked samples, Biosimilar with Humira\u00ae spiked samples, and clinical samples from patients treated with adalimumab biosimilar. All of these samples were spiked with polyclonal antibodies directed against Humira\u00ae. Specificity inhibition and specificity detection steps were also part of the validation parameters. Reagents made with ABP501 gave similar results than reagents made with Humira\u00ae meeting acceptance criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>LISA-TRACKER ADA and anti-ADA assays are reliable for the monitoring of patients treated with ABP501.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12865-021-00473-1","type":"journal-article","created":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T06:02:32Z","timestamp":1640412152000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)"],"prefix":"10.1186","volume":"22","author":[{"given":"Fabien","family":"Francois","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loubna","family":"Naimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Roblin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Emmanuelle","family":"Berger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8830-4273","authenticated-orcid":false,"given":"Stephane","family":"Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,25]]},"reference":[{"issue":"2","key":"473_CR1","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/apt.14420","volume":"47","author":"J-F Colombel","year":"2018","unstructured":"Colombel J-F, Sandborn WJ, Reinisch W, et al. Long-term safety of adalimumab in clinical trials in adult patients with Crohn\u2019s disease or ulcerative colitis. Aliment Pharmacol Ther. 2018;47(2):219\u201328. https:\/\/doi.org\/10.1111\/apt.14420.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"473_CR2","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1080\/14712598.2017.1309390","volume":"17","author":"MP Sparrow","year":"2017","unstructured":"Sparrow MP. Adalimumab in ulcerative colitis\u2014efficacy, safety and optimization in the era of treat-to target. Expert Opin Biol Ther. 2017;17(5):613\u201321. https:\/\/doi.org\/10.1080\/14712598.2017.1309390.","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"473_CR3","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.semarthrit.2017.03.008","volume":"47","author":"F Cantini","year":"2017","unstructured":"Cantini F, Niccoli L, Nannini C, et al. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Semin Arthritis Rheum. 2017;47(2):183\u201392. https:\/\/doi.org\/10.1016\/j.semarthrit.2017.03.008.","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"473_CR4","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s10067-017-3890-4","volume":"37","author":"CK Correll","year":"2018","unstructured":"Correll CK, Bullock DR, Cafferty RM, Vehe RK. Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis. Clin Rheumatol. 2018;37(2):549\u201353. https:\/\/doi.org\/10.1007\/s10067-017-3890-4.","journal-title":"Clin Rheumatol"},{"issue":"5","key":"473_CR5","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1504370","volume":"375","author":"AB Kimball","year":"2016","unstructured":"Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375(5):422\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1504370.","journal-title":"N Engl J Med"},{"issue":"3","key":"473_CR6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1080\/1744666X.2017.1288097","volume":"13","author":"KC LaMattina","year":"2017","unstructured":"LaMattina KC, Goldstein DA. Adalimumab for the treatment of uveitis. Expert Rev Clin Immunol. 2017;13(3):181\u20138. https:\/\/doi.org\/10.1080\/1744666X.2017.1288097.","journal-title":"Expert Rev Clin Immunol"},{"key":"473_CR7","unstructured":"AbbVie Reports Full-Year and Fourth-Quarter 2019 Financial Results. AbbVie. https:\/\/investors.abbvie.com\/news-releases\/news-release-details\/abbvie-reports-full-year-and-fourth-quarter-2019-financial. Accessed 27 Feb 2020."},{"key":"473_CR8","unstructured":"U.S. Department of Health and Human Services. Food and Drug Administration. Clinical pharmacology data to support a demonstration of biosimilarity to a reference product: guidance for industry. 2016:15."},{"issue":"1","key":"473_CR9","doi-asserted-by":"crossref","first-page":"122","DOI":"10.33590\/emjrheumatol\/10314875","volume":"6","author":"A Valido","year":"2019","unstructured":"Valido A, Ara\u00fajo FC, Fonseca JE, Gon\u00e7alves J. A review of adalimumab biosimilars for the treatment of immune-mediated rheumatic conditions. EMJ Rheumatol. 2019;6(1):122\u201333.","journal-title":"EMJ Rheumatol"},{"issue":"10","key":"473_CR10","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1136\/annrheumdis-2016-210459","volume":"76","author":"S Cohen","year":"2017","unstructured":"Cohen S, Genovese MC, Choy E, et al. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. Ann Rheum Dis. 2017;76(10):1679\u201387. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210459.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"473_CR11","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1093\/ecco-jcc\/jjz018","volume":"13","author":"K Papamichael","year":"2019","unstructured":"Papamichael K, Juncadella A, Wong D, et al. Proactive therapeutic drug monitoring of adalimumab is associated with better long-term outcomes compared with standard of care in patients with inflammatory bowel disease. J Crohns Colitis. 2019;13(8):976\u201381. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjz018.","journal-title":"J Crohns Colitis"},{"key":"473_CR12","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000565","author":"A Jentzer","year":"2018","unstructured":"Jentzer A, Berger A-E, Labetoulle R, Haccourt A, Roblin X, Paul S. Evaluation of infliximab and anti-infliximab LISA-TRACKER immunoassays for the therapeutic drug monitoring of SB2 infliximab biosimilar. Ther Drug Monit. 2018. https:\/\/doi.org\/10.1097\/FTD.0000000000000565.","journal-title":"Ther Drug Monit"},{"key":"473_CR13","doi-asserted-by":"publisher","DOI":"10.1177\/1756284819828238","author":"C Rocha","year":"2019","unstructured":"Rocha C, Afonso J, Lago P, et al. Accuracy of the new rapid test for monitoring adalimumab levels. Ther Adv Gastroenterol. 2019. https:\/\/doi.org\/10.1177\/1756284819828238.","journal-title":"Ther Adv Gastroenterol"},{"issue":"Suppl 2","key":"473_CR14","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1136\/annrheumdis-2019-eular.2373","volume":"78","author":"MB Ruiz-Arg\u00fcello","year":"2019","unstructured":"Ruiz-Arg\u00fcello MB, Maguregui A, Mart\u00ednez A, Nagore D. Ab0404 validation of a therapeutic drug monitoring test to measure the adalimumab biosimilar Sb5 in comparison with the reference adalimumab. Ann Rheum Dis. 2019;78(Suppl 2):1662\u20133. https:\/\/doi.org\/10.1136\/annrheumdis-2019-eular.2373.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"473_CR15","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1136\/annrheumdis-2019-eular.2360","volume":"78","author":"MB Ruiz-Arg\u00fcello","year":"2019","unstructured":"Ruiz-Arg\u00fcello MB, Maguregui A, Mart\u00ednez A, Nagore D. Ab0405 adalimumab therapeutic drug monitoring test validated for measuring Abp 501 biosimilar. Ann Rheum Dis. 2019;78(Suppl 2):1663\u20131663. https:\/\/doi.org\/10.1136\/annrheumdis-2019-eular.2360.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"473_CR16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11894-017-0559-8","volume":"19","author":"C Sheasgreen","year":"2017","unstructured":"Sheasgreen C, Nguyen GC. The evolving evidence for therapeutic drug monitoring of monoclonal antibodies in inflammatory bowel disease. Curr Gastroenterol Rep. 2017;19(5):19. https:\/\/doi.org\/10.1007\/s11894-017-0559-8.","journal-title":"Curr Gastroenterol Rep"},{"issue":"7","key":"473_CR17","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1111\/apt.14943","volume":"48","author":"B Verstockt","year":"2018","unstructured":"Verstockt B, Moors G, Bian S, et al. Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn\u2019s disease patients: the usefulness of rapid testing. Aliment Pharmacol Ther. 2018;48(7):731\u20139. https:\/\/doi.org\/10.1111\/apt.14943.","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"473_CR18","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1093\/ibd\/izy044","volume":"24","author":"S Restellini","year":"2018","unstructured":"Restellini S, Chao C-Y, Lakatos PL, et al. therapeutic drug monitoring guides the management of Crohn\u2019s patients with secondary loss of response to adalimumab. Inflamm Bowel Dis. 2018;24(7):1531\u20138. https:\/\/doi.org\/10.1093\/ibd\/izy044.","journal-title":"Inflamm Bowel Dis"},{"key":"473_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215546","author":"H Marotte","year":"2019","unstructured":"Marotte H, Rinaudo-Gaujous M, Petiet C, Fautrel B, Paul S. Tapering without relapse in rheumatoid arthritis patients with high TNF blocker concentrations: data from STRASS study. Ann Rheum Dis. 2019. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215546.","journal-title":"Ann Rheum Dis"},{"issue":"suppl 10","key":"473_CR20","first-page":"3730","volume":"67","author":"S Candon","year":"2015","unstructured":"Candon S, Chatenoud L, Brocq O, Perdriger A, Lassoued S, Berthelot J-M. Interest of assessing anti-drug antibodies for the choice between a second anti-TNF and a non-TNF-targeted biologic in patients with inadequate response to a first anti-TNF: results from the randomized controlled trial \u00abRotation or Change\u00bb. Arthritis Rheumatol. 2015;67(suppl 10):3730\u20131.","journal-title":"Arthritis Rheumatol"},{"key":"473_CR21","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaa001","author":"M Lukas","year":"2020","unstructured":"Lukas M, Malickova K, Kolar M, et al. Switching from originator adalimumab to the biosimilar SB5 in patients with inflammatory bowel disease: short-term experience from a single tertiary clinical centre. J Crohns Colitis. 2020. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaa001.","journal-title":"J Crohns Colitis"},{"issue":"2","key":"473_CR22","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/bjd.18220","volume":"182","author":"J Hercogov\u00e1","year":"2020","unstructured":"Hercogov\u00e1 J, Papp KA, Chyrok V, Ullmann M, Vlachos P, Edwards CJ. AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis. Br J Dermatol. 2020;182(2):316\u201326. https:\/\/doi.org\/10.1111\/bjd.18220.","journal-title":"Br J Dermatol"},{"issue":"3","key":"473_CR23","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/bjd.16890","volume":"179","author":"A Blauvelt","year":"2018","unstructured":"Blauvelt A, Lacour J-P, Fowler JF, et al. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches. Br J Dermatol. 2018;179(3):623\u201331. https:\/\/doi.org\/10.1111\/bjd.16890.","journal-title":"Br J Dermatol"},{"issue":"10","key":"473_CR24","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1080\/14712598.2019.1564033","volume":"19","author":"G Fiorino","year":"2019","unstructured":"Fiorino G, Gilardi D, Correale C, et al. Biosimilars of adalimumab: the upcoming challenge in IBD. Expert Opin Biol Ther. 2019;19(10):1023\u201330. https:\/\/doi.org\/10.1080\/14712598.2019.1564033.","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"473_CR25","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12876-017-0654-1","volume":"17","author":"L Gonczi","year":"2017","unstructured":"Gonczi L, Kurti Z, Rutka M, et al. Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases. BMC Gastroenterol. 2017;17(1):97. https:\/\/doi.org\/10.1186\/s12876-017-0654-1.","journal-title":"BMC Gastroenterol"}],"container-title":["BMC Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-021-00473-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12865-021-00473-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-021-00473-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T08:24:36Z","timestamp":1674203076000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcimmunol.biomedcentral.com\/articles\/10.1186\/s12865-021-00473-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["473"],"URL":"https:\/\/doi.org\/10.1186\/s12865-021-00473-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-44850\/v1","asserted-by":"object"}]},"ISSN":["1471-2172"],"issn-type":[{"value":"1471-2172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"21 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No competing interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"81"}}